Frontlight ResearchEarly access
Active, not recruitingPhase 2
The NOVA-NOA Trial A Novel Aromatase Inhibitor, Leflutrozole, for Treatment of Non-Obstructive Azoospermia
Key facts
- Who runs it
- Herlev Hospital
- Where
- Denmark1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 15 people, planned
- Started
- 30 Jun 2026
- Expected to end
- 15 Apr 2027
- Type of study
- Interventional
- Record updated
- 14 October 2026
Who can take part
- Age
- 18 years to 64 years
- Sex
- Men only
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Signed informed consent by participant
- Signed informed consent by participant’s partner (must just be obtained before the participant starts treatment at Visit 1), if applicable, regarding blood samples, data col-lection about fertility treatment as well as pregnancy and pregnancy outcome
- 18-55 years
- Azoospermia verified by at least 2 semen samples, average semen volume >= 1,0 ml with no identifiable sign of obstruction (samples taken at Visit -1 and at Visit 0 prior to confirmation of eligibility and dosing)
- Serum AMH or Inhibin B level above the lower limit of quantification (LLOQ) at screening or within 6 months prior to screening
- Testosterone < 15 nmol/L at screening or within 6 months prior to screening
- Serum estradiol above the lower limit of normal range (48 pmol/L) at screening or within 6 months prior to screening
Who cannot take part
- Use of any prescription or non-prescription medication (apart from routine vitamins, occasional use of paracetamol, acetylsalicylic acid, or ibuprofen) which could interfere with pharmacokinetic or pharmacodynamic results, as judged by the investigator, such as: o Herbal products and non-routine vitamins o Insulin o Medication such as systemic corticosteroids, tricyclic antidepressants, and atypical antipsychotics
- Surgery scheduled for the trial duration period, except for minor, non-gastrointestinal surgical procedures at the discretion of the investigator
- Hematocrit >50% at screening or within 6 months prior to screening
- Current abuse of steroids
- Prior thromboembolic event within the last 24 months
- Klinefelter or other major genetic conditions including large deletions on sex chromo-somes
- Cancer (past or present, except basal cell skin cancer or squamous cell skin cancer), which in the investigator’s opinion could interfere with the results of the trial
- Severe chronic diseases requiring daily medication
- Serum prostate specific antigen (PSA) > 3 ng/mL at screening or within 6 months prior to screening
- Osteoporosis requiring medical treatment
- Mental incapacity, language barriers or unwillingness to comply with the requirements of the protocol, which may preclude adequate understanding or co-operation during the trial, as judged by the investigator
- Average testis size > 20 mL unless obstruction has been excluded
- TESE procedure < ½ year ago
- LH concentration > 15 IU/L at screening
- BMI > 45 kg/m2
- Cardiovascular event within the last 6 months judged as significant by the investigator
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this intervention is to investigate whether the aromatase inhibitor, Leflutrozole, can improve semen quality in a subgroup of infertile men
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 14 October 2026